| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 10.02.
| UBS belässt Shire auf 'Buy' - Ziel 2.470 Pence | | 71 | APA-dpa-AFX-Analyser |
| Die UBS hat die Einstufung für Shire
nach Zahlen auf "Buy" mit einem Kursziel von 2.470 Pence belassen.
Der Pharmakonzern habe ein starkes Zahlenwerk sowohl für das vierte
Quartal als auch für...
Mehr lesen zu:
UBS belässt Shire auf 'Buy' - Ziel 2.470 Pence | |
| 09.02.
| Shire Beats Estimates on Top and Bottom Lines | | 1 | Motley Fool |
| 09.02.
| Shire 4Q profit soars 55 percent behind drug sales | | 2 | Yahoo-USA |
| 09.02.
| UPDATE 2-Shire's profit boosted by ADHD, rare disease drugs | | - | Reuters.com |
| 09.02.
| Here's Why Shire's Latest Report Might Worry You | | - | Motley Fool |
| 09.02.
| ROUNDUP: Shire Q4 Profit Rises, EPS Tops View; Sees Earnings Growth In 2012 | | 42 | AFX News |
| SAINT HELIER (dpa-AFX) - Specialty pharmaceutical company Shire plc (SHP.L,
SHPGY) on Thursday said profit in the fourth quarter increased significantly
from last year, amid strong demand...
Mehr lesen zu:
ROUNDUP: Shire Q4 Profit Rises, EPS Tops View; Sees Earnings Growth In 2012 | |
| 09.02.
| Shire Q4 Profit Rises | | 43 | AFX News |
| SAINT HELIER (dpa-AFX) - Shire plc (SHP.L, SHPGY) reported that its
fourth-quarter net income was $263.7 million, up from $173.5 million in the
same quarter last year. On a US GAAP basis...
Mehr lesen zu:
Shire Q4 Profit Rises | |
| 09.02.
| Another Strong Year for Shire With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34 | | 44 | PR Newswire |
| DUBLIN, Ireland, February 9, 2012 /PRNewswire/ --
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the year to December 31, 2011.
Financial...
Mehr lesen zu:
Another Strong Year for Shire With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34 | |
| 09.02.
| Shire plc: Another strong year for Shire | | - | InvestEgate |
| 09.02.
| SHIRE PLC - Another strong year for Shire | | 21 | PR Newswire |
| Another strong year for Shire with revenues exceeding $4 billion for the first
time and Non GAAP EPS up 26% to $5.34.
Good 2012 earnings growth expected.
February 9, 2012 - Shire plc (LSE:...
Mehr lesen zu:
SHIRE PLC - Another strong year for Shire | |
| 08.02.
| FDA clears Shire Vyvanse capsules for ADHD | | - | Pharma Bus Review |
| 07.02.
| Shire and Sangamo Cut a Deal | | 24 | Zacks |
| 07.02.
| Shire Gets FDA Approval To Expand ADHD Drug Vyvanse To Adults, Stock Up | | 37 | AFX News |
| SAINT HELIER (dpa-AFX) - Shire plc (SHP.L,SHPGY) Tuesday announced that the
US Food and Drug Administration approved the prescription medication Vyvanse
(lisdexamfetamine dimesylate) Capsules...
Mehr lesen zu:
Shire Gets FDA Approval To Expand ADHD Drug Vyvanse To Adults, Stock Up | |
| 07.02.
| Shire plc (SHPGY) Gets FDA Approval for Adult ADHD Medication Vyvanse | | 1 | StreetInsider.com |
| 07.02.
| Market overview: Shire shining, Glaxo gloomy | | 2 | ShareCast |
| 07.02.
| Market overview: Shire leads gains on Goldman note | | 1 | ShareCast |
| 07.02.
| Shire leads FTSE risers on upgrade and bid talk, but markets cautious on Greece | | 6 | Guardian |
| 06.02.
| Vodafone rises as it calls off Greek merger, while Shire climbs on bid talk | | 4 | Guardian |
| 06.02.
| Shire Rising Today on Above-Average Volume | | 1 | SmarTrend |
| 02.02.
| Shire partners Sangamo to develop hemophilia treatments | | 58 | Pharma Bus Review |
